苏黄止咳胶囊治疗感冒后咳嗽的系统评价

目的 系统评价苏黄止咳胶囊治疗感冒后咳嗽的疗效和安全性。方法 检索2007年1月-2015年6月,万方数据库、中国知识网(CNKI)全文数据库、维普数据库(VIP)及中国生物医学光盘数据库中有关苏黄止咳胶囊治疗感冒后咳嗽的临床随机对照研究。采用RevMan 5.0软件对纳入的文献进行定量综合分析。结果 检索到42篇文献,按照纳入和排除标准,最终入选9篇;Meta分析提示,试验组(苏黄止咳胶囊组)治疗感冒后咳嗽的临床疗效[愈显率OR=3.15,95%CI为2.33~4.26,P<0.00001;痊愈率OR=12.30,95%CI为1.64~3.25,P<0.00001;有效率OR=4.65,95%CI为3.10~6.98,P<0.00001]与对照组相比有统计学意义;不良反应发生率[OR=1.09,95%CI为0.29~4.14,P>0.05]与对照组比较无统计学意义。结论 苏黄止咳胶囊治疗感冒后咳嗽的临床疗效好,不良反应少。

Systemastic review of Suhuang Zhike Capsule in treatment of post-cold cough

Objective To evaluate the efficacy and safety of Suhuang Zhike Capsule (SZC) in the treatment of post-cold cough. Methods Computer retrieval of Wanfang, CNKI, VIP, and CBM on SZC in the treatment of post-cold cough clinical randomized controlled study (RCTs). Reaching time from January 2007 to June 2015. The control study was carried out by RevMan5.0 software. Results Totally 42 papers were preliminary retrieved in strict accordance with the inclusion and exclusion criteria, nine papers were finally selected. Meta-analysis suggested that the clinical efficacies of experimental groups (SZC groups) in the treatment of post-cold cough were as follows:[healing rate OR=3.15, 95%CI 2.33-4.26, P<0.00001; cure rate OR=12.30, 95%CI 1.64-3.25, P<0.00001; effective rate OR=4.65, 95%CI 3.10-6.98, P<0.00001]. Compared with the control group, there was statistical significance. Incidence of adverse reactions[OR=1.09, 95%CI:0.29-4.14, P>0.05], compared with the control group, there was no statistical significance. Conclusion The clinical efficacy of SZC in the treatment of post-cold cough clinical effect is good, and the adverse reaction is little.